Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2018-09-13 Capital/Financing Update
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, describing an offering of 4,500,000 common shares by Xenon Pharmaceuticals Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. The document is a registration and offering prospectus supplement, which is a capital raising document related to a share issuance. It is not a financial report, earnings release, or management discussion. The presence of underwriting details, offering price, and share issuance terms clearly indicate this is a Capital/Financing Update filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-09-13 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an underwriting agreement for a public offering of common shares, termination of a material definitive agreement, and unregistered sales of equity securities. It includes details about the offering price, number of shares, and related agreements. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The document is not a report publication announcement but an actual filing reporting significant corporate events related to capital raising. Therefore, it fits best under Capital/Financing Update (CAP).
2018-09-13 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to a common share offering by Xenon Pharmaceuticals Inc. It includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and company overview. The document references SEC registration statements and is filed pursuant to Rule 424(b)(5), which is a form used for prospectus supplements related to securities offerings. The content focuses on the terms and details of a capital raise through common shares, including underwriting discounts and commissions, use of proceeds, and risk disclosures. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or quarterly report, audit report, earnings release, or any other category. Therefore, the correct classification is CAP with high confidence.
2018-09-12 English
8-K - ATM SUSPENSION
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 12, 2018. It announces the suspension of an at-the-market equity offering and related details about the company's securities offering activities. The content is an update on financing activities rather than a full financial report or earnings release. The document length is 3134 characters, which is relatively short and focused on a specific event. The key phrase 'suspended... any securities pursuant to the prospectus supplement' indicates a capital/financing update. Therefore, the document fits best under the Capital/Financing Update (CAP) category.
2018-09-12 English
Regulatory Filings 2018
Regulatory Filings
2018-09-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a Milestone and Royalty Buy-Out Agreement) and includes details about the agreement and related press release. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a significant corporate event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5563 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content.
2018-09-11 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.